The **EGFR** rs2233947 polymorphism is associated with lung cancer risk: a study from Jordan

Nabil A. Bashir1, Farah R. Moradi1, Omar F. Khabour2, Mahmoud A. AlFAQih1 and Basheer Y. Khassawneh3

1Department of Physiology and Biochemistry, Faculty of Medicine, 2Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, 3Department of Internal Medicine, Faculty of Medicine, Jordan University of Science and Technology, Irbid 22110, Jordan

The epidermal growth factor receptor (EGFR) is a tyrosine kinase cell surface protein that plays a role in the process of carcinogenesis. In this study, we investigated the association between **EGFR** rs2233947 and rs884225 SNPs and the risk of lung cancer. A total of 258 participants (129 lung cancer patients and 129 healthy controls) took part in the study. Restriction fragment length polymorphism-polymerase chain reaction (RFLP-PCR) technique was used to genotype **EGFR** SNPs. A strong association was detected between rs2233947 and lung cancer (P<0.01). Compared with the rs2293347 GG genotype, the AA/AG genotypes were associated with a significantly decreased risk of lung cancer (adjusted OR = 0.28, 95% confidence interval [CI]=0.13–0.61, P<0.01). EGFR rs2233947 correlated with lung cancer in males, smokers, and in the squamous cell carcinoma lung cancer subtype (P<0.01). Haplotype analysis of rs2233947 and rs884225 showed that the AA haplotype was associated with a significantly decreased risk of lung cancer (P<0.01). The data presented in the current study support a protective role for the rs2233947 A allele against the development of lung cancer. This result, however, requires further validation in a larger population.

**Key words**: EGFR, Jordan, lung cancer, polymorphism, rs2233947, rs884225

**Received**: 20 February, 2019; revised: 04 August, 2019; accepted: 12 August, 2019; available on-line: 13 September, 2019

**INTRODUCTION**

Lung cancer is among the leading causes of cancer deaths worldwide (McIntyre & Ganti, 2017). It is estimated that 2 million people succumb to lung cancer on an annual basis (Wong et al., 2017). Factors which increase the risk of lung cancer include tobacco use, radon exposure and air pollution (Brennan et al., 2011; Field & Withers, 2012; Young & Hopkins, 2011). For example, exposure to tobacco smoke (active or second-hand) has been shown to account for the majority of lung cancer (IARC, 2012). In addition to the above environmental factors, genetic predisposition appears to play a role in determining or modifying lung cancer risk. Indeed, for several genes, it has been shown that a variation in sequence or copy number is implicated in the development of lung cancer or in modifying lung cancer risk. These genes include epidermal growth factor receptor (EGFR), vascular endothelial growth factor, ataxia telangiectasia mutated, the cytochrome P450 family 1 subfamily A member 1, and many others (Farago & Az-Zoli, 2017; Feng et al., 2014; Hussein et al., 2014; Xu et al., 2017; Yang et al., 2018).

Among the many genes shown to be associated with lung cancer, EGFR received considerable attention. EGFR is a member of the cell surface receptor tyrosine kinase family (Sato, 2013) and was shown in several studies to play a pivotal role in the carcinogenesis of several solid tumors (Mitsudomi & Yatabe, 2010). Following stimulation by its ligands, EGFR elicits a downstream cell-signaling cascade which promotes proliferation, invasion, metastasis, angiogenesis, and inhibition of apoptosis (Brand et al., 2013; Takahashi et al., 2015). Several studies demonstrated that genetic variations in **EGFR** were involved in determining or modifying the risk of lung cancer development and/or progression (Dubey et al., 2006; Sasaki, Endo et al., 2008; Sasaki, Okuda et al., 2008; L. Zhang et al., 2013; Zhang et al., 2006). Additionally, in several studies, genetic variations in **EGFR**, including single nucleotide polymorphisms, were shown to modulate the response of lung cancer patients to a number of lung cancer therapies including tyrosine kinase inhibitors; a class of targeted therapies effective against a number of solid malignancies (Bonomi et al., 2018; Jung et al., 2012; Li et al., 2018; X. Liu et al., 2017; Y. Liu et al., 2013; Metro et al., 2018).

In Jordan, lung cancer is the third most common cancer, following breast and colorectal cancers (Ismail et al., 2013). A recent study has shown an association between **EGFR** rs712829 and rs2072454 SNPs with the risk of lung cancer among Jordanians (Bashir et al., 2018). In the current investigation, the relationship between two other SNPs in **EGFR** (rs2233947 and rs884225) and lung cancer risk was studied.

**METHODS**

**Participants.** The study was case-control in design. Patient recruitment took place at two large tertiary referral centers in Jordan (King Abdullah University Hospital and King Hussein Cancer Center) between January 2016 and December 2017. A total of 129 healthy participants matched to patients by age, sex and smoking were recruited from the same geographical areas to act as a control group. The study was approved by the Institutional Review Board of Jordan University of Science and Technology (approval number 12/93/2016) and followed the guidelines of the Helsinki declaration regarding medical research involving human participants. Written consent...
was received from all the participants after full explanation of the study aims and procedures. Patients with primary lung cancer were included in the study regardless of the cancer type or stage. Medical diagnoses were performed by a respiratory consultant and were further confirmed by a histopathology examination. Patients with secondary lung cancer were excluded from the study (Bashir et al., 2018).

**Samples and data collection.** A structured questionnaire was used to collect demographic data (e.g. age, gender and toxicant exposure). Clinical data were collected from patients’ medical records. For molecular analysis, 3 mL of venous blood were collected from each participant to the EDTA sterile tubes.

**DNA extraction.** DNA was extracted from whole blood using commercially available kits (Puregene Blood Core Kit B, Germantown, MD, USA). The quality and concentration of the isolated DNA were analyzed using a Thermo Scientific NanoDrop ND-2000 UV-Vis Spectrophotometer (Waltham, MA, USA). Samples were stored at –80°C until further use.

**Genotyping of EGFR rs2233947 and rs884225 SNPs.** Information about *EGFR* rs2233947 and rs884225 SNPs was obtained from the National Center for Biotechnology Information SNP database (http://www.ncbi.nlm.nih.gov/SNP). PCR primers were designed using the Gen-Bank reference sequence (accession no. NT_033968) and NCBI primer blast system (https://www.ncbi.nlm.nih.gov/tools/primer-blast/). The selected primers were 5'-ATTGGGAAAA CACACAGG-CCAC-3' (forward) and 5'-CTGCTGAAGAA GCCTCTGTC-3' (reverse) for rs2233947; and 5'-AGAAAGGAGGGGATGAAT-3' and 5'-AGGATTTCCA-CATTCTCAGC-3' (reverse) for rs884225. PCR reactions were performed in a 25 μl reaction volume containing 5 μL genomic DNA, 1 μL (10 pM) of each primer, 12.5 μL Promega green mix (USA) and 6.5 μL nuclease free water. PCR was performed using Applied Bio systems Veriti Thermal Cycler (Foster City, CA, USA). The amplification conditions were: an initial denaturation step at 95°C for 7 min, followed by 40 cycles of 1 min at 95°C, 1 min at 56°C and 1 min at 72°C; with a final extension step at 72°C for 10 min. Amplified DNA fragments (240 bp for rs2233947 and 279 bp for rs884225) were visualized on a 2% agarose gel stained with ethidium bromide. The PCR products were digested overnight with the appropriate restriction enzymes (MLyI used for rs2233947 and AGII for rs884225, New England Bio Labs, Beverly, MA, USA). Digestion reactions were performed according to the manufacturer’s recommendations. The digested PCR products were resolved on a 3% agarose gel with ethidium bromide and visualized under UV light using a G:BOX UV with dedicated software (Syngene, Frederick, MD, USA). The Chi-square test and SNP stat tool for co-dominant, dominant, and recessive were utilized to analyze the association between tested polymorphisms and lung cancer. *P* value of <0.05 was applied as an indication of statistical significance.

**RESULTS**

Table 1 shows demographics of study participants. The control group (n=129) was matched to the group of patients with lung cancer, considering the major environmental risk factors and did not show significant differences of gender, age and smoking status (*P*>0.05). About 81.4% of participants were males. The majority of participants were either ever smokers (83.7%) or ex-smokers (9.3%), with an average of 1.5±0.43 pack per day and a smoking history of more than 20 years.

According to the histopathological diagnosis (Table 2), the lung cancer patients were classified into the following groups: adenocarcinoma (31.8%), squamous cell (38.8%), small cell/large cell (8.5%), and non-small cell cancer of unidentified histology (10.1%). The majority of cases (69.8%) was diagnosed at a late stage (III and IV) and 55.0% had distant metastasis (Table 2).

The genotype/allele frequencies of the *EGFR*, rs2293347 and rs884225 polymorphisms among the patients and controls, and their association with lung cancer risk are shown in Table 3. The distributions of genotypes of both SNPs in the control group were within the Hardy-Weinberg equilibrium (*P>*0.05). The frequency of the rs2293347 genotype differed significantly between the patients and controls (GG, AG and AA genotypes; 90%, 8% and 2% in patients versus 82%, 15% and 3% in controls, respectively). Table 2. Characteristics of lung cancer patients taking part in this study. The majority of patients were smokers, diagnosed with squamous cell carcinoma or adenocarcinoma and presented at a late stage.

| Variable                        | n (%) |
|---------------------------------|-------|
| **Histopathology**              |       |
| Adenocarcinoma                  | 41 (31.8) |
| Squamous cell                   | 50 (38.8) |
| Small/Large cell                | 11 (8.5) |
| NSCLC                           | 13 (10.1) |
| Not Available                   | 14 (10.9) |
| **Clinical staging**            |       |
| I/II                            | 20 (15.5) |
| III                             | 22 (17.1) |
| IV                              | 68 (52.7) |
| Not Available                   | 19 (14.7) |
| **Metastasis**                  |       |
| Metastasis                      | 71 (55.0) |
| No Metastasis                   | 39 (30.2) |
| Not Available                   | 19 (14.6) |

Table 1. Demographic characteristics of study population.

| Characteristics | Cases (n=129) | Controls (n=129) | *P* value |
|-----------------|---------------|------------------|-----------|
| Mean age ±S.D.  | 61.8±9.9      | 61.6±10.1        | 0.8730    |
| Sex: n (%)      |               |                  |           |
| Males           | 105 (81.4%)   | 105 (81.4%)      | 1.0       |
| Females         | 24 (18.6%)    | 24 (18.6%)       |           |
| Smoking Status: |               |                  |           |
| Yes             | 108 (83.7%)   | 108 (83.7%)      | 1.0       |
| No              | 21 (16.3%)    | 21 (16.3%)       |           |
pared with the rs2293347 GG genotype, the AG/AA genotypes were associated with a significantly decreased risk of lung cancer (adjusted odds ratio [OR]=0.28, 95% confidence interval [CI]=0.13–0.61, \( P =0.0022 \)).

The association between the rs2293347 genotype and the risk of lung cancer was further examined after stratifying the study population according to gender, smoking status, and histological type (Table 4).

With respect to rs884225, there was no significant association between this SNP and lung cancer (\( P >0.05 \)). Distribution of the genotypes was similar in lung cancer patients and in controls (GG, AG and AA genotypes: 2.3%, 17.1% and 80.6% in patients versus 0.8%, 17.8% and 81.4% in controls, respectively (Table 3). Similarly, the allelic distribution of rs884225 was similar between the two groups, with the A allele being the most common (about 90% in both groups, Table 3).

Finally, Table 5 summarizes haplotype analysis of \( EGFR \) rs2293347 and rs884225 SNPs. The G/A haplotype was the most frequent haplotype in the population (80%), followed by the A/A haplotype (9%). The A/A haplotype was more frequent in controls (13.6%) than in patients with lung cancer (4.9%) and was associated with a significantly decreased risk of lung cancer (adjusted OR=0.37, 95% CI=1.19–2.72, \( P =0.004 \), global \( P <0.05 \), Table 5).

**DISCUSSION**

The current study addressed the association between \( EGFR \) rs2293347 and rs884225 SNPs and lung cancer. The results showed strong association between rs2293347 and lung cancer with the A allele being protective against the development of lung cancer.

The role of \( EGFR \) pathway in the regulation of cellular growth is well documented (Lui & Grandis, 2002). Activation of \( EGFR \) has been implicated in cellular proliferation, angiogenesis and survival (Brand, et al., 2013; Takeuchi & Ito, 2010). \( EGFR \) exerts its functions via dimerization and auto-phosphorylation of the tyrosine kinase domain of the protein. This activates signal
transduction pathways that upregulate transcription factors and control expression of downstream genes (Sheppard et al., 2008). Somatic mutations in the tyrosine kinase region can lead to constitutive activation of the receptor and the initiation of carcinogenesis. Likewise, certain EGFR genetic variations have also been shown to change EGFR protein levels in the body, including lungs (Nie et al., 2015), and subsequently modulate cancer susceptibility. In accordance with this, the variations in EGFR gene have been shown to modulate risk of several types of cancers, including gastric (Torres-Jasso et al., 2015), bladder (Chu et al., 2013), breast (Sobti et al., 2012) and lung cancer (Bashir et al., 2018; Feng et al., 2014; X. Liu et al., 2017).

The results of the present study showed a strong association between EGFR rs2293347 and lung cancer, with the A allele being protective against cancer development. When patients were stratified according to type of lung cancer, the association was found to be prominent in the squamous cell carcinoma subtype. In accordance with this finding, a study conducted in the Korean population showed a strong relationship between rs2293347 SNP and lung cancer, with the A allele being associated with a significantly decreased risk of lung cancer (Choi et al., 2007). Similarly, rs2293347 SNP was suggested as a risk factor for the development of gastric cancer (Zhang et al., 2013). In general, the clinical significance of the rs2293347 SNP has been reported. It was found to be associated with the efficiency of tyrosine kinase inhibitors in patients with non-small cell lung cancer (Ma et al., 2011; Zhang et al., 2006), and it has been shown to contribute to benign prostatic hyperplasia (Kim et al., 2016) and airway hyperresponsiveness (Yoshikawa & Kanazawa, 2012). Furthermore, the rs2293347 SNP has been shown to be a significant predictor of the prolonged progression-free and overall survival in an independent cohort of EGFR mutation-positive lung cancer patients treated with erlotinib (Winther-Larsen et al., 2019). Finally, using a knowledge-based bioinformatic approach, the rs2293347 was found to be among the best predictors of TKIs response in gastric cancer (Takahashi et al., 2015). Thus, the results of the current study together with those of others indicate that rs2293347 SNP in EGFR gene plays a clinical role in some malignancies, including lung cancer.

It is worth to mention that the rs2233947 is a synonymous SNP located in exon 25 of the gene and it does not result in an amino acid change in the EGFR protein. Therefore, this polymorphism cannot influence the way by which the EGFR protein mediates its function. However, in some cases, synonymous SNPs can impact gene expression by several mechanisms that include modulation of RNA splicing, stability and its interactions with the translational machinery (Lee et al., 2011; Shas try, 2009; Venza et al., 2010). Alternatively, the observed effect of rs2233947 on risk of lung cancer can be due to the presence of linkage disequilibrium between this SNP with unidentified polymorphism in the EGFR gene (Choi et al., 2007). Further research is required to understand the mechanism by which the rs2233947 modulates its clinical effects.

The EGFR rs884225 SNP is located within a predicted binding site for micro RNA (miRNA-214). Therefore, this SNP might be of clinical significance as it has been shown to be associated with changes in EGFR gene expression (Chu et al., 2013). However, the results of the present study showed a lack of association between rs884225 and lung cancer. This is in agreement with a study that was conducted in a Chinese population and showed no association between rs884225 and nasopharyngeal carcinoma (Liu et al., 2013). However, in one study, the GG genotype of rs884225 was found to be associated with a significantly increased risk of bladder cancer (Chu et al., 2013) and with response to tyrosine kinase inhibitors in the Chinese lung cancer patients (Ruan et al., 2016). Thus, the effects of rs884225 SNP might have a population or cancer type specific component, being affected by the genetic background and/or interactions with environmental factors.

Literature suggests that the association tests based on haplotypes provide greater statistical power than the tests based on the underlying SNPs (Bader 2001; Lin & Schaid, 2009). Therefore, the association of lung cancer with haplotype of rs2233947 and rs884225 was performed, showing that the AA haplotype was associated with a significantly decreased risk of lung cancer. This result supports a role of the rs2233947 A allele in the development of lung cancer.

One of the limitations of the current study is that it did not address the relationship between rs2233947 and rs884225 SNPs of EGFR gene and the clinical parameters of lung cancer (prognosis, stages, and metastasis). Future studies that include such parameters are strongly recommended.

In conclusion, the rs2233947 SNP is associated with risk of lung cancer among the Jordanian population. More studies are required to confirm this finding in other populations.

Acknowledgement

The authors would like to thank the Ministry of Higher Education – Scientific Research Fund (SRF) and Jordan University of Science and Technology for their support.

Conflict of Interest

Authors have nothing to declare

REFERENCES

Bader JS (2001) The relative power of SNPs and haplotype as genetic markers for association tests. Pharmgenomics 2: 11–24. https://doi.org/10.1517/14622416.2.1.11

Bashir NA, Ragab ES, Khabour OF, Khassawneh BY, Alfaqih MA, Momani JA (2018) The association between epidermal growth factor receptor (EGFR) gene polymorphisms and lung cancer risk. BioMed Research International 8: https://doi.org/10.1155/2018/8050053

Bonomi PD, Gandara D, Hirsch FR, Kerr KM, Oba sau C, Paz-Ares L, Bellomo C, Bradley JD, Bunn PA, Jr., Calligan M, Jett JR, Kim ES, Langer CJ, Natale RB, Novello R, Perol M, Ramalingam SS, Reck M, Reynolds CH, Smit EF, Soeinski MA, Spigel DR, Vanteenikste JF, Wakelee H, Thatecher N (2018) Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer. Ann Oncol 29: 1701–1709. https://doi.org/10.1016/j.annonc.2017.09.011

Brand TM, Ida M, Luther N, Sarr MM, Huppert EJ, Wheeler DL (2013) Nuclear EGFR as a molecular target in cancer. Radiat Oncol 8: https://doi.org/10.1186/1479-5876-8-53

Choi JE, Park SH, Kim KM, Lee WK, Kam S, Cha SI, Kim CH, Kang YM, Kim YC, Han SB, Jung TH, Park JY (2007) Polymorphisms in the epidermal growth factor receptor gene and the risk of primary lung cancer: a case-control study. BMC Cancer 7: 199. https://doi.org/10.1186/1471-2407-7-199

Chu H, Wang M, Jin H, Lv Q, Wu D, Tong N, Ma I, Shi D, Zhong Z (2013) EGFR 3′UTR 774T>C polymorphism contributes to bladder cancer risk. Mutagenesis 28: 49–55. https://doi.org/10.1093/mutage/geo051

Dubey S, Stephenson P, Levy DE, Miller JA, Keller SM, Schiller JH, Johnson DH, Kolesar JM, Eastern Cooperative Oncology G (2006)
EGFR dinsucleotide repeat polymorphism as a prognostic indicator in non-small cell lung cancer. J Thorac Oncol 11: 128–135. https://doi.org/10.1097/JTO.0000000000000359

Field RW, Withers BL (2012) Occupational and environmental causes of lung cancer. Clin Chest Med 33: 681–705. https://doi.org/10.1016/j.ccm.2012.07.001

Hussein AG, Pasha HF, El-Shahat HM, Gad DM, Toam MM (2014) CYP1A1 gene polymorphisms and smoking status as modifiers for lung cancer risk. Gene 541: 26–30. https://doi.org/10.1016/j.gene.2014.03.003

Ismail SI, Soubani M, Nimmi JM, Al-Zeer AH (2013) Cancer incidence in Jordan from 1990 to 2009—a comprehensive study. Asian Pac J Clin Oncol 7: 325–334. https://doi.org/10.1155/2012.53.6.087

Jung M, Cho BC, Lee CH, Park HS, Kang YA, Kim SK, Chang J, Kim DJ, Rha SY, Kim JH, Lee JH (2012) EGFR polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKIs. Yonsei Med J 53: 1128–1135. https://doi.org/10.3349/ymj.2012.53.6.1128

Kim SK, Park HK, Choi HS, Yoo KH, Chung JH (2016) Association study of polymorphisms of epithelial growth factor and epithelial growth factor receptor with benign prostatic hyperplasia in a Korean population. Int Neurourol J 20: 363–370. https://doi.org/10.5213/intjim.1632583.269

Lee JH, Kim KW, Gee HY, Lee J, Lee KH, Park HS, Kim SH, Kim SW, Kim MN, Kim KE, Kim KH, Lee MG, Sohn MH (2011) A synonymous variation in protease-activated receptor-2 is associated with atopy in Korean children. J Allergy Clin Immunol 128: 1326–1334.e123. https://doi.org/10.1016/j.jaci.2011.06.036

Li X, Wang S, Li B, Wang Z, Shang S, Shao Y, Sun X, Wang L (2018) BIM deletion polymorphism confers resistance to Osimertinib in EGFR T790M lung cancer: a case report and literature review. Target Oxlmed 3: 1–6. https://doi.org/10.1007/s13523-017-0136-3

Lin WY, Schaad DJ (2009) Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family. J Clin Invest 118: 3574–3581. https://doi.org/10.1172/JCI36099

Sobti RC, Askari M, Nikhuldit M, Singh N, Sharma SC, Abiteb AM (2012) Genetic variants of EGFR (442858G>A) and ESR1 (442858G>A) gene polymorphisms and risk of breast cancer. Mol Cell Biochem 369: 217–225. https://doi.org/10.1007/s11010-012-1384-x

Stelig MA, Dresler CM (2011) Epidemiology of lung cancer: smoking, secondhand smoke, and genetics. Surg Oncol Clin N Am 20: 605–618. https://doi.org/10.1016/j.soc.2011.07.003

Takahashi H, Kanwah N, Sato Y, Sai K, Hamaguchi T, Shirao K, Shimada Y, Matsumara Y, Ohtsu A, Yoshino T, Doi T, Takahashi A, Odaka Y, Okuyama M, Sawada J, Sakamoto H, Yoshida T (2015) Construction of possible integrated predictive index based on EGFR mutation and ANXA3 gene polymorphism in fluoropyrimidine-treated Japanese gastric cancer patients using a bioinformatic method. BMC Cancer 15: 718. https://doi.org/10.1186/s12885-015-1722-2

Takeuchi K, Ito (2010) EGFR receptor in relation to tumor development: molecular basis of responsiveness of cancer cells to EGFR-targeting tyrosine kinase inhibitors. FEBS J 277: 316–326. https://doi.org/10.1111/j.1742-4658.2009.07480.x

Torres-Jasso JH, Martin ME, Santiago-Luna F, Leonor JC, Torres J, Magana-Torres MT, Pera FJ, Ibarras B, Sanchez-Lopez JY (2015) EGFR gene polymorphisms -216G>T and -191C>A are risk markers for gastric cancer in Mexican population. Genet Mol Biol 14: 1802–1807. https://doi.org/10.1590/2013.53.6.019

Venza M, Catalano T, Visalli M, Venza I, Lentini M, Curia MC, Mariani Costantini R, Tetti D (2010) Association of the DSSI c.143G>A polymorphism with skin squamous cell carcinoma. J Invest Dermatol 130: 1719–1725. https://doi.org/10.1038/jid.2010.21

Winther-Larsen A, Fynboe Elbert EB, Meldgaard P, Sorensen BS (2019) EGFR gene polymorphism predicts improved outcome in patients with EGFR mutation-positive non-small cell lung cancer treated with Erlotinib. Clin Lung Cancer 20: 161–166 e161. https://doi.org/10.1016/j.cllc.2019.02.011

Wong MCS, Lao XQ, Ho KF, Goggins WB, Tse SLA (2017) Incidence of smoking in Hong Kong: a comprehensive study. Asian Pac J Cancer Prev 18: 1271–1277. https://doi.org/10.17265/1469-6688.2017.03.019

Xu Y, Gao P, Lv X, Zhang L, Zhang J (2017) The role of the ataxia telangiectasia mutated gene in lung cancer: recent advances in research. Thor A Stero Dirit 11: 375–380. https://doi.org/10.1177/1753456X17725716

Yang F, Qin Z, Shao C, Liu W, Ma L, Shu Y, Shen H (2018) Association between VEGF C gene polymorphisms and the Susceptibility to Lung Cancer: An Updated Meta-Analysis. Biomed Res Int 2018: 9271215. https://doi.org/10.1155/2018/9271215

Yoshikawa T, Kanazawa H (2012) Integrated effect of EGFR and PAR-1 signaling crosstalk on airway hypertresponsiveness. Int J Mol Med 30: 41–48. https://doi.org/10.3892/ijmm.2012.981

Young RP, Hopkins RJ (2011) How the genetics of lung cancer may overlap with COPD. Respiratory 15: 1047–1055. https://doi.org/10.1183/09001111.114.1440.1843.2011.02019.x

Zheng BS, Qin JJ, Zheng BS, Huang LL, Xie XY, Zhou HF (2014) Association of epidermal growth factor receptor (EGFR) gene polymorphism with lung cancer risk: a systematic review. J Reoprt Signal Traitand Res 34: 333–334. https://doi.org/10.3109/1799832.2014.885052

Zheng H, Zou J, Wang X, Li K, Cao Q, Li D, He C, Sun Y, Peng F (2021) EGFR polymorphism and the kinase domain in Japanese lung cancer. J Surg Oncol 134: 532–539. https://doi.org/10.1002/jso.29304

Zhang J, Zhan Z, Wu J, Zhang C, Yang Y, Tong S, Wang R, Yang X, Dong W, Chen Y (2013) Relationship between EGF, TGFA, and EGFR polymorphism and smoking status in Chinese non-small cell lung cancer patients. Lung Cancer 80: 168–173. https://doi.org/10.1016/j.lungcan.2013.06.017

Zhang Q, Zhan Z, Wu J, Zhang C, Yang Y, Tong S, Wang R, Yang X, Dong W, Chen Y (2013) Relationship between EGF, TGFA, and EGFR polymorphism and smoking status in Chinese non-small cell lung cancer patients. Lung Cancer 80: 168–173. https://doi.org/10.1016/j.lungcan.2013.06.017

Zhang W, Stabile LP, Keohavong P, Romkes M, Grandis JR, Traynor AM, Siegfried JM (2006) Mutation and polymorphism in the EGFR-TK domain associated with lung cancer. J Thorac Oncol 1: 658–647.